Navigation Links
Access Licenses MuGard(TM) to RHEI Pharmaceuticals, a Leading Specialty Pharmaceutical Company for Distribution in China and Certain Other Southeast Asian Countries
Date:1/14/2008

DALLAS and NEW HAVEN, Conn., Jan. 14 /PRNewswire-FirstCall/ -- Access Pharmaceuticals, Inc. (OTC Bulletin Board: ACCP) and RHEI Pharmaceuticals, Inc. ("RHEI"), a specialty pharmaceutical company focused on bringing proprietary medicines to the China market, today announced the signing of a definitive licensing agreement under which RHEI, which has more than 110 national sales representatives penetrating large volume hospitals, will market Access's proprietary product MuGard(TM) in the Peoples Republic of China and certain other Southeast Asian countries. MuGard(TM) has received marketing allowance from the U.S. Food and Drug Administration for the management of oral mucositis, a debilitating side effect of many anticancer treatments. Oral mucositis has become a significant unmet medical need as a result of improved medical care in China and the Southeast Asian region. RHEI will be responsible for marketing MuGard in the People's Republic of China, Hong Kong, Macau, Taiwan, Brunei, Cambodia, Indonesia, Laos, Malaysia, Myanmar, Philippines, Singapore, Thailand and Vietnam, as well as for manufacturing and for obtaining the necessary regulatory approvals for the product in the territory.

"We are pleased to have MuGard in our portfolio of products in China, building on our expertise in the area of oncology," said Dr. X. Sylvia He, Chief Executive Officer of RHEI. "Our mission is to bring innovative products to the Chinese market and MuGard fulfills a real medical need. With an increasing number of patients receiving radiation and chemotherapy in China, the prevalence of oral mucositis is growing. Our expert capabilities in sales and marketing, manufacturing and regulatory will help to maximize MuGard's potential in the marketplace."

"RHEI is a great partner for us in China," added Jeffrey B. Davis, Chief Executive Officer of Access. "We are excited about the potential for MuGard in China and believe RHEI is uniquely positioned to commercialize MuGar
'/>"/>

SOURCE Access Pharmaceuticals, Inc.; RHEI Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. GAO Report Confirms: Medicare Underpays for Anesthesia Services; Nurse Anesthetists Assure Seniors Access to Safe Anesthesia Care
2. Report on patients access to cancer drugs uses flawed methods to reached flawed conclusions
3. Open access to health research publications
4. Patient Advocate Foundation Launches Program to Help Uninsured Virginians with Chronic, Debilitating and Life-Threatening Illness Access Quality Healthcare
5. Care reforms raise concerns over patient access to GP services
6. Access Innovations Provides Support Services for Agis Network
7. RAND researchers offer options to improve immigrant health care quality, access
8. Uninsured community health center patients often have difficulty accessing specialty services
9. Hispanics hypertension better controlled with equal access to care
10. PA Health Department Survey Shows Impact of Income, Gender, Other Factors on Health and Access to Health Care
11. More than 10,000 Medicare Patients in Montana Could Be Hit by Proposed Cuts to Home Oxygen Therapy; Access to Power Wheelchairs Would Also Decrease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2014)... New research led by a scientist at the University ... key element in the development of the nervous system ... of breast cancer., A research team, led by ... the Department of Biology at York, has studied how ... tumours. These channels are found in the membranes of ...
(Date:4/23/2014)... Moffitt Cancer Center researchers say clinical trials for ... leukemia (AML) are very promising. Patients treated with ... and daunorubicin, are showing better responses than patients ... , "Acute myeloid leukemia is an aggressive ... success, especially in older patients," explained Jeffrey Lancet, ...
(Date:4/23/2014)... Fairfax, Va., April 23, 2014 The American Society ... guideline, "The Role of Postoperative Radiation Therapy for ... the use of adjuvant radiation therapy in the ... is published in the May-June 2014 issue of ... clinical practice journal of ASTRO. The full-length guideline ...
(Date:4/23/2014)... N.Y. A novel compound that targets an important ... of cocaine addiction behaviors, including relapse behavior, a University ... provides strong evidence that this may be a novel ... effective medications exist., The UB research was published as ... week. , In the study, the compound, RO5263397, severely ...
(Date:4/23/2014)... detection methods that can rapidly screen a large ... cell inside that population has been seriously lacking," ... In the Royal Society of Chemistry journal ... and his coworkers have developed a novel technique ... ( Chem. Sci. , 2014, DOI: 10.1039/C4SC00578C, ...
Breaking Medicine News(10 mins):Health News:Breast cancer replicates brain development process 2Health News:Moffitt Cancer Center's phase 3 study may be game-changer for acute myeloid leukemia 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Novel compound halts cocaine addiction and relapse behaviors 2Health News:Following a protein's travel inside cells is key to improving patient monitoring, drug development 2
... elements include platform updates and product road map ... Healthcare developers,can take the next step toward increasing ... 1.3 of Microsoft Health Common User,Interface (CUI), available ... guidance, software toolkit controls and showcase demonstrators,the Microsoft ...
... LONDON, May 13 Chiltern, a leading global ... office in Lisbon,Portugal. Mr. Ricardo Diaz will head ... over 10 years experience in clinical research and,holds ... Clinical trials and,an MBA., The office is ...
... with California Environmental ... Quality Act (CEQA)., LOS ... ahead with the planned expansion of its,Holy Cross Medical Center even ... the approval process was significantly flawed.,The groundbreaking ceremony held today appears ...
... Corporation,(Nasdaq: IOMI ) today said that it will ... today,s announcement that Intercell AG (VSE:,ICLL) and Iomai have ... acquire Iomai for USD 6.60 per share representing a ... 122 million)., The conference call and webcast will ...
... 12 Emphasys Medical Inc.,today announced that one-year ... Zephyr(R) Endobronchial Valve (EBV) will be presented at ... occurring,May 16 to 21 in Toronto, Canada., ... Convention Centre,Room 801A, In the symposium, "Innovations ...
... 12, 2008) - Beta-blocker drugs may help prevent heart ... of death and major stroke, says a major study ... journal, The Lancet. , POISE is the worlds largest ... the effects of a beta-blocker versus placebo given to ...
Cached Medicine News:Health News:Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety 2Health News:Updated Microsoft Health Common User Interface Furthers Clinical Effectiveness, Increases Patient Safety 3Health News:Chiltern Announces New Expansion in Portugal 2Health News:Providence Holy Cross Medical Center Ignores Community, Environmental Concerns With Planned Expansion of Mission Hills Facility 2Health News:Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT 2Health News:Iomai to Host Conference Call and Webcast Tomorrow, Tuesday, May 13, at 8:30 a.m. EDT 3Health News:Emphasys Medical to Present VENT Clinical Trial Data at ATS 2008 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 2Health News:Metoprolol around the time of surgery increases the risk of death and stroke: POISE trial 3
(Date:1/15/2014)... , Jan. 15, 2014 Reportlinker.com ... is available in its catalogue: ... Advanced Drug Delivery Systems -- Focus on ... STUDY OBJECTIVES A ...
(Date:1/15/2014)... , Jan. 15, 2014  A novel wearable injector slightly larger ... painless for patients to self-inject prescription drugs in the large ... cancer, blood diseases, autoimmune deficiencies, and genetic disorders.  ... to $220B by 2018, according to analysts.   Many of these ...
(Date:1/14/2014)... N.J. , Jan. 14, 2014 InformEx, ... and sellers of high-value chemistry, will hold the 30 th ... Miami Beach Convention Center from January 21-24. ... 3,500 attendees from top pharmaceutical, fine chemical and specialty chemical ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 16Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 17Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on End Users 18Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
... DIEGO, June 8, 2011 Otonomy, Inc., ... of the ear, today announced positive results for OTO-201, ... in multiple preclinical studies evaluating the treatment of middle ... placement surgery.  Approximately one million tube placement procedures are ...
... NORTH KINGSTOWN, R.I., June 8, 2011 Leading national ... Tufts Health Care Institute,s (THCI) Program on Opioid Risk ... support of THCI,s Program on Opioid Risk Management began ... promoting the safe and effective use of controlled opioid ...
Cached Medicine Technology:Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 2Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 3Otonomy Announces Preclinical Results Supporting Intra-operative Use of OTO-201 for Common Childhood Procedure 4Dominion Diagnostics Supports Opioid Risk Management Program for Fourth Consecutive Year 2
... Keep your samples secure in our largest ... storage - enough for 52,700 samples -- ... this ultra-low temperature model utilizes ultra-thin vacuum ... and minimize the footprint. Patented Tollesbury Technology ...
... III, laboratory-grade pure water at a constant ... potable tap water and combine complementary purification ... is easy to operate, reliable, and allows ... a low operating cost., Applications, Glassware ...
... U570 is an upright freezer, built ... models. Comparable in size to Innova ... cascade refrigeration and urethane insulation, for ... 400 2" boxes. Includes five compartments ...
... chest freezer utilizes ultra-thin vacuum insulation ... without increasing the footprint. Patented Tollesbury ... compressor life. Bright LED display shows ... for remote user-supplied monitoring system. Keyed ...
Medicine Products: